Christian Rommel

Executive Vice President, Global Head of Research & Development; Member of the Executive Committee

Bayer AG

Dr. Christian Rommel became EVP, Global Head of Research & Development, and a member of the executive committee of Bayer Pharmaceuticals in February 2021. In this role, he is also a member of board of directors at BlueRock Therapeutics, AskBio and Vividion Therapeutics – wholly-owned, independently operated subsidiaries of Bayer AG.

He joined Bayer from Roche, where he was most recently Senior VP, Global Head of Oncology, Pharma Research and Early Development (pRED). Rommel also served at Amgen as Vice President of External Research and Development. Before that role, he was Amgen’s Vice President, Research Oncology.

Previously, Christian Rommel served as Chief Scientific Officer of Intellikine, a private biotech company based in San Diego, from its inception to acquisition by Takeda. Earlier in his career, Rommel was Head of Target Research at Merck-Serono in Geneva, Switzerland. He also worked as a scientist in the team of George Yancopoulos at Regeneron Pharmaceuticals, New York.

Christian Rommel received his PhD in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland. He is also a lecturer of biotechnology at the ETH Zurich, Switzerland. He has authored more than 70 publications, including papers in Science and Nature and is an inventor or co-inventor of 18 patents.

Outside of work, Christian Rommel very much enjoys spending time with his family, good food paired with a good glass of wine as well as art and skiing.